<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Biotechnology concern Novavax, Inc. ( NASDAQ:NVAX) is plummeting today, last seen down 18.6% to trade at $192.20, after the drug maker said it would not seek emergency use authorization from the U.S. Federal Drug Administration (FDA) for its coronavirus vaccine until the fourth quarter, delaying the process one more time as it struggles to access raw materials and equipment.
...read full article on Schaeffers Research
